GlassScriptPhysician profile
Jean H Mcclintock
NPI 1134167687
$15,117.01
in general payments reported to CMS, 2019-2025
38 companies · $3,273 in 2025
The $3,273 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,320 · 2020: $999 · 2021: $1,114 · 2022: $2,013 · 2023: $2,389 · 2024: $3,009 · 2025: $3,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,511 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,511.23 |
| Education | $159.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,315.86 | 2019-2025 | |
| Genzyme Corporation | $1,189.26 | 2019-2025 | |
| Janssen Biotech, INC. | $1,168.04 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,104.46 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $674.75 | 2023-2025 | Zoryve |
| Amgen INC. | $658.98 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $614.92 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $586.40 | 2022-2025 | Opzelura |
| Biofrontera INC. | $581.40 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $519.26 | 2019-2024 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $480.31 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $464.23 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $413.82 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $397.19 | 2020-2021 | |
| Ucb, INC. | $339.66 | 2022-2025 | Bimzelx |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $315.14 | 2020-2025 | |
| Galderma Laboratories, L.P. | $285.53 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Leo Pharma INC. | $278.03 | 2019-2025 | Adbry |
| Pfizer INC. | $243.91 | 2019-2025 | |
| Davol INC. | $189.94 | 2025 | Arista |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $168.98 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Almirall LLC | $142.91 | 2019-2025 | Klisyri |
| Sebela Pharmaceuticals INC. | $142.64 | 2019-2020 | |
| Allergan, INC. | $103.35 | 2019-2022 | |
| Celgene Corporation | $102.50 | 2019 | |
| Janssen Scientific Affairs, LLC | $100.00 | 2019 | |
| Organon LLC | $98.37 | 2025 | Vtama |
| Revance Therapeutics, INC. | $74.08 | 2024-2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.58 | 2023-2025 | Spevigo |
| Dermavant Sciences, INC. | $59.98 | 2023-2024 | Vtama |
| Astellas Pharma US INC | $50.22 | 2025 | Veozah |
| Verrica Pharmaceuticals INC. | $46.66 | 2023-2024 | Ycanth |
| Epi Health, LLC | $37.89 | 2022 | |
| Botanix Sb INC | $25.89 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $23.44 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.94 | 2019 | |
| Dermira, INC. | $16.81 | 2020 | |
| Strata Skin Sciences, INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Mcclintock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.